High-intensity focused ultrasound ablation in the treatment of recurrent ovary cancer and metastatic pelvic tumors: a feasibility study

References

• Salani R, Backes F, Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–478.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1):34–43.
   PubMed Web of Science ®Google Scholar
• Trimbos J, Parmar M, Vergote I, European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2):105–112.
   PubMed Web of Science ®Google Scholar
• Elit L, Fyles A, Devries M, Gynecology Cancer Disease Site Group, et al. Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol. 2009;114(3):528–535.
   PubMed Web of Science ®Google Scholar
• Temple W, Saettler E. Locally recurrent rectal cancer: role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence. J Surg Oncol. 2000;73(1):47–58.
   PubMed Web of Science ®Google Scholar
• Liu J, Barry W, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–1214.
   PubMed Web of Science ®Google Scholar
• Chiantera V, Rossi M, De Iaco P, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer. 2014;24(1):156–164.
   PubMed Web of Science ®Google Scholar
• Garcia-Ortega D, Villa-Zepeda O, Martinez-Said H, et al. Oncology outcomes in Retroperitoneal sarcomas: prognostic factors in a Retrospective Cohort study. Int J Surg. 2016;32:45–49.
   PubMed Web of Science ®Google Scholar
• Konofaos P, Spartalis E, Moris D, et al. Challenges in the surgical treatment of retroperitoneal sarcomas. Indian J Surg. 2016;78(1):1–5.
   PubMed Web of Science ®Google Scholar
• Jain V, Sekhon R, Giri S, et al. Robotic-assisted video endoscopic inguinal lymphadenectomy in carcinoma vulva: our experiences and intermediate results. Int J Gynecol Cancer. 2017;27(1):159–165.
   PubMed Web of Science ®Google Scholar
• Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005;5(4):321–327.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang ZB. High-intensity focused ultrasound tumor ablation: review of ten years of clinical experience. Front Med China. 2010; 4(3):294–302.
   PubMedGoogle Scholar
• Lam N, Rivens I, Giles S, et al. Prediction of pelvic tumour coverage by magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) from referral imaging. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology. Int J Hyperthermia. 2020; 37(1):1033–1045.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chiang P. Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre. PloS One. 2020;15(7):e0236026
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Intervent Radiol. 2009;20(7):S377–SS90.
   PubMed Web of Science ®Google Scholar
• Hong J, Tsai C, Lai C, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(1):249–257.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Guerrieri M, Cosio S. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. Crit Rev Oncol Hematol. 2019;135:103–114.
   PubMed Web of Science ®Google Scholar
• Choi M, Moon Y, Jung S, et al. Real-world experience with pembrolizumab treatment in patients with heavily treated recurrent gynecologic malignancies. Yonsei Med J. 2020;61(10):844–850.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang G, Liu Y, et al. [Surgical concept and techniques of recurrent cervical cancer patients accompanied with high risk of intestinal obstruction after radical radiotherapy]]. Zhonghua Zhong Liu Za Zhi. 2020;42(1):61–64.
   PubMedGoogle Scholar
• van Driel W, Koole S, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Berek J, Howe C, Lagasse L, et al. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecologic Oncology. 2005;99(1):153–159.
   PubMed Web of Science ®Google Scholar
• Jurado M, Alcázar J, Martinez-Monge R. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration: is still the clinical involvement of the pelvis wall a real contraindication? a twenty-year experience. Gynecologic Oncology. 2010;116(1):38–43.
   PubMed Web of Science ®Google Scholar
• Deng H, Wang J, Wang Z, et al. [Outcomes of perisurgery and short-time follow-up of pelvic exenteration for 17 cases with locally recurrent cervical cancer]. Zhonghua Fu Chan Ke Za Zhi. 2020;55(4):259–265.
   PubMedGoogle Scholar
• Schmidt A, Imesch P, Fink D, et al. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol. 2012;125(3):604–609.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Imesch P, Fink D, et al. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients. Int J Gynecol Cancer. 2016;26(4):716–721.
   PubMed Web of Science ®Google Scholar
• Berretta R, Marchesi F, Volpi L, et al. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: clinical and functional outcome. Taiwanese J Obstet Gynecol. 2016;55(3):346–350.
   PubMed Web of Science ®Google Scholar
• Berretta R, Capozzi V, Sozzi G, et al. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer. Arch Gynecol Obstet. 2018;297(4):997–1004.
   PubMed Web of Science ®Google Scholar
• Wu R, Hu B, Jiang LX, et al. High-intensity focused ultrasound in ovarian cancer xenografts. Adv Ther. 2008;25(8):810–819.
   PubMed Web of Science ®Google Scholar
• Liu X, Tang J, Luo Y, et al. Comparison of high-intensity focused ultrasound ablation and secondary myomectomy for recurrent symptomatic uterine fibroids following myomectomy: a retrospective study. BJOG. 2020;127(11):1422–1428.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang W, He M, et al. Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases. Int J Hyperthermia. 2018;35(1):56–61.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Yue Y, Shui L, et al. Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for the treatment of patients with adenomyosis and prior abdominal surgical scars: a retrospective study. Int J Hyperthermia. 2015;31(7):777–783.
   PubMed Web of Science ®Google Scholar